LYCA.US Lycia Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
31.20 USD
Close of Nov 15, 2026
22.19 36.49
Market cap
USD 1.63B
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is LYCA.US undervalued?

Graham number

The Graham number of Lycia Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lycia Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Lycia Therapeutics, Inc. Common Stock yet.

Lycia Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lycia Therapeutics, Inc. Common Stock

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of a…

Full company profile